Home > Insider Trading > Filing (0001181431-13-035721)

Filing Details

Accession Number:: 0001181431-13-035721
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-06-19 16:00:38
Reporting Period:: 2013-06-17

Filing Date:: 2013-06-19
Accepted Time:: 2013-06-19 16:00:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1527134	Mark Sumeray	C/O Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-06-17	6,000	$13.01	6,000	No	4	M	Direct
Common Stock	Disposition	2013-06-17	1,809	$63.05	4,191	No	4	S	Direct
Common Stock	Disposition	2013-06-17	791	$63.86	3,400	No	4	S	Direct
Common Stock	Disposition	2013-06-17	1,000	$65.36	2,400	No	4	S	Direct
Common Stock	Disposition	2013-06-17	900	$66.67	1,500	No	4	S	Direct
Common Stock	Disposition	2013-06-17	1,400	$67.73	100	No	4	S	Direct
Common Stock	Disposition	2013-06-17	100	$68.44	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2013-06-17	6,000	$0.00	6,000	$13.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
142,000		2021-11-01	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.62 to $64.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.80 to $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.29 to $67.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.39 to $68.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
100,000 shares of common stock underlying this option vest over a 46-month period, with one-twenty-fourth of the shares vesting on the grant date of November 1, 2011 and the remainder of the shares vesting monthly thereafter in forty-six equal installments; 30,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Juxtapid by the U.S. Food and Drug Administration; 20,000 shares of common stock underlying this option vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Juxtapid by the European Medicines Agency; and 10,000 shares of common stock underlying this option vest monthly in equal installments over a four-year period commencing upon approval of Juxtapid for the treatment of pediatric patients.